168 related articles for article (PubMed ID: 15746068)
21. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
[TBL] [Abstract][Full Text] [Related]
22. Induction of HLA class I-restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections.
Kim SK; Angevine M; Demick K; Ortiz L; Rudersdorf R; Watkins D; DeMars R
J Immunol; 1999 Jun; 162(11):6855-66. PubMed ID: 10352308
[TBL] [Abstract][Full Text] [Related]
23. A partially agonistic peptide acts as a selective inducer of apoptosis in CD8+ CTLs.
Wei CH; Beeson C; Masucci MG; Levitsky V
J Immunol; 1999 Sep; 163(5):2601-9. PubMed ID: 10452999
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets.
Mailliard RB; Lotze MT
Clin Cancer Res; 2001 Mar; 7(3 Suppl):980s-988s. PubMed ID: 11300500
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
[TBL] [Abstract][Full Text] [Related]
26. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.
Darrow TL; Abdel-Wahab Z; Quinn-Allen MA; Seigler HF
Cell Immunol; 1996 Aug; 172(1):52-9. PubMed ID: 8806806
[TBL] [Abstract][Full Text] [Related]
27. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
Valmori D; Dutoit V; Rubio-Godoy V; Chambaz C; Liénard D; Guillaume P; Romero P; Cerottini JC; Rimoldi D
Cancer Res; 2001 Jan; 61(2):509-12. PubMed ID: 11212242
[TBL] [Abstract][Full Text] [Related]
28. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
[TBL] [Abstract][Full Text] [Related]
29. Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro.
Byers DE; Lindahl KF
J Immunol; 1999 Sep; 163(6):3022-8. PubMed ID: 10477565
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
31. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
Latouche JB; Sadelain M
Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
[TBL] [Abstract][Full Text] [Related]
32. Correlation between direct binding ability of synthetic T. gondii SAG1 peptides to HLA-A2 measured by a sensor for surface plasmon resonance and antigenicity of the peptides for T. gondii-infected cell-specific CTL.
Yano A; Aosai F; Yang TH; He N; Mun HS; Liu H; Inoko H; Norose K
Biochem Biophys Res Commun; 1997 Jul; 236(2):257-61. PubMed ID: 9240420
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.
Yotnda P; Garcia F; Peuchmaur M; Grandchamp B; Duval M; Lemonnier F; Vilmer E; Langlade-Demoyen P
J Clin Invest; 1998 Jul; 102(2):455-62. PubMed ID: 9664088
[TBL] [Abstract][Full Text] [Related]
34. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
[TBL] [Abstract][Full Text] [Related]
35. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.
Khanna R; Burrows SR; Thomson SA; Moss DJ; Cresswell P; Poulsen LM; Cooper L
J Immunol; 1997 Apr; 158(8):3619-25. PubMed ID: 9103423
[TBL] [Abstract][Full Text] [Related]
36. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
37. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.
Pellat-Deceunynck C; Jego G; Harousseau JL; Vié H; Bataille R
Clin Cancer Res; 1999 Mar; 5(3):705-9. PubMed ID: 10100725
[TBL] [Abstract][Full Text] [Related]
38. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer.
Calogero A; Hospers GA; Krüse KM; Schrier PI; Mulder NH; Hooijberg E; de Leij LF
Anticancer Res; 2000; 20(3A):1793-9. PubMed ID: 10928109
[TBL] [Abstract][Full Text] [Related]
39. Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide.
Hooijberg E; Visseren MJ; van den Berk PC; Jellema AP; Romeijn P; Sein JJ; van der Voort EI; Hekman A; Ossendorp F; Melief CJ
J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):346-56. PubMed ID: 8941874
[TBL] [Abstract][Full Text] [Related]
40. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
